Ameneh Eshghinejad: The First 72 Hours After SAH Are Critical for Balancing the Risks of Rebleeding and Thromboembolism
Ameneh Eshghinejad, Intensive Care Nurse at Milad hospital, shared a post on LinkedIn:
”The 72-Hour Rule After SAH… is not just a timeline. It’s a decision that can change a life.
In the ICU, we live in the space between two risks:
Rebleeding… versus Thromboembolism
After an aneurysmal subarachnoid hemorrhage (SAH), the question isn’t if anticoagulation is needed – it’s when it becomes safe enough.
And that’s where many clinicians hesitate.
Here’s the practical bedside approach:
0–24 hours:
No anticoagulation.
Mechanical prophylaxis only (IPC).
Your priority equals protect the brain.
24–48 hours:
Start VTE prophylaxis (low-dose heparin or enoxaparin)
Only if:
- No active bleeding
- Imaging is stable
Greater than or equal to 72 hours:
Now we reassess everything.
If the patient is:
- Aneurysm secured (clipped/coiled)
- Clinically and radiologically stable
- No hematoma expansion
This is your green light for therapeutic anticoagulation.
The Bedside Rule you should never forget:
Secured plus Stable plus 72 hours equals Go (carefully)
But here’s the part we don’t always talk about…
I once cared for a patient post-SAH—young, previously healthy.
We delayed anticoagulation, fearing rebleeding.
On day 4, everything looked ‘stable.’
But before escalation… they developed a massive pulmonary embolism.
That moment stays with you.
Because in critical care, waiting is also a decision.
And sometimes… it costs more than acting.
This is why precision matters.
Not just protocols. Not just guidelines.
But clinical judgment, timing, and courage to reassess.”

Stay updated with Hemostasis Today.
-
Aug 14, 2026, 06:26Delivering Gene Therapy in Hemophilia – ISTH
-
Aug 13, 2026, 18:39Lukas Röthlisberger: Real-World Evidence on Effectiveness and Safety of Rivaroxaban in Children
-
Aug 13, 2026, 18:36Soner Yilmaz: Blood Safety in Türkiye Through More Than 22.5 Million Blood Donations
-
Aug 13, 2026, 18:31Muthukumarasamy Raja: FDA Approval of EZPLAZ Marks a Breakthrough in Emergency Plasma Care
-
Aug 13, 2026, 18:29Peter Zdziarski: Protecting Our Community While Creating a Future Where We Are No Longer Needed
-
Aug 13, 2026, 18:29Morgan E Amos: Thrilled to Receive the Student Research Award From HTRS
-
Aug 13, 2026, 16:38Sheharyar Raza: Plasma Exchange in Multiple Sclerosis
-
Aug 13, 2026, 16:31Juan Manuel Cisneros Carrasco: The True Cost of Blood Donation
-
Aug 13, 2026, 16:25Connie Montgomery: Bridging the Gap Between Patients, Culture and Clinical Trials